Peng-Xia Wan, Department of Ophthalmology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China.
World J Stem Cells. 2015 Mar 26;7(2):448-60. doi: 10.4252/wjsc.v7.i2.448.
Cell therapy is a promising treatment for diseases that are caused by cell degeneration or death. The cells for clinical transplantation are usually obtained by culturing healthy allogeneic or exogenous tissue in vitro. However, for diseases of the eye, obtaining the adequate number of cells for clinical transplantation is difficult due to the small size of tissue donors and the frequent needs of long-term amplification of cells in vitro, which results in low cell viability after transplantation. In addition, the transplanted cells often develop fibrosis or degrade and have very low survival. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS) are also promising candidates for cell therapy. Unfortunately, the differentiation of ESCs can bring immune rejection, tumorigenicity and undesired differentiated cells, limiting its clinical application. Although iPS cells can avoid the risk of immune rejection caused by ES cell differentiation post-transplantation, the low conversion rate, the risk of tumor formation and the potentially unpredictable biological changes that could occur through genetic manipulation hinder its clinical application. Thus, the desired clinical effect of cell therapy is impaired by these factors. Recent research findings recognize that the reason for low survival of the implanted cells not only depends on the seeded cells, but also on the cell microenvironment, which determines the cell survival, proliferation and even reverse differentiation. When used for cell therapy, the transplanted cells need a specific three-dimensional structure to anchor and specific extra cellular matrix components in addition to relevant cytokine signaling to transfer the required information to support their growth. These structures present in the matrix in which the stem cells reside are known as the stem cell microenvironment. The microenvironment interaction with the stem cells provides the necessary homeostasis for cell maintenance and growth. A large number of studies suggest that to explore how to reconstruct the stem cell microenvironment and strengthen its combination with the transplanted cells are key steps to successful cell therapy. In this review, we will describe the interactions of the stem cell microenvironment with the stem cells, discuss the importance of the stem cell microenvironment for cell-based therapy in ocular diseases, and introduce the progress of stem cell-based therapy for ocular diseases.
细胞治疗是一种有前途的治疗方法,可用于治疗由细胞变性或死亡引起的疾病。用于临床移植的细胞通常通过在体外培养健康的同种异体或外源性组织获得。然而,对于眼部疾病,由于组织供体体积小以及细胞在体外长期扩增的频繁需求,获得足够数量的用于临床移植的细胞很困难,这导致移植后细胞活力降低。此外,移植的细胞常常发生纤维化或降解,存活率非常低。胚胎干细胞(ESCs)和诱导多能干细胞(iPS)也是细胞治疗的有前途的候选者。不幸的是,ESCs 的分化可能带来免疫排斥、致瘤性和不理想的分化细胞,限制了其临床应用。尽管 iPS 细胞可以避免移植后 ESC 分化引起的免疫排斥风险,但低转化率、肿瘤形成风险以及通过遗传操作可能发生的潜在不可预测的生物学变化阻碍了其临床应用。因此,这些因素影响了细胞治疗的理想临床效果。最近的研究结果表明,植入细胞存活率低的原因不仅取决于接种的细胞,还取决于细胞微环境,细胞微环境决定了细胞的存活、增殖甚至逆转分化。当用于细胞治疗时,除了相关的细胞因子信号外,移植细胞还需要特定的三维结构来固定和特定的细胞外基质成分,以将所需的信息传递给细胞以支持其生长。这些结构存在于干细胞所在的基质中,被称为干细胞微环境。微环境与干细胞的相互作用为细胞的维持和生长提供了必要的内稳态。大量研究表明,探索如何重建干细胞微环境并加强其与移植细胞的结合是成功细胞治疗的关键步骤。在这篇综述中,我们将描述干细胞微环境与干细胞的相互作用,讨论干细胞微环境对于眼部疾病的细胞治疗的重要性,并介绍基于干细胞的眼部疾病治疗的进展。